title: [Teriflunomide is a new peroral disease-modifying drug for multiple sclerosis (a review)].
abstract: Teriflunomide is a once-daily, orally administered, disease-modifying drug. The review presents the data concerning the mechanism of action, pharmacokinetics as well as results of clinical studies. Teriflunomide has received the regulatory approval in the USA, Argentina, Australia, South Korea, Chile and EU. The submission of a regulatory dossier is performed in Russia.
authors.forename: O V
authors.initials: OV
authors.lastname: Boĭko
authors.forename: I D
authors.initials: ID
authors.lastname: Stoliarov
authors.forename: A M
authors.initials: AM
authors.lastname: Petrov
authors.forename: A N
authors.initials: AN
authors.lastname: Boĭko
mesh_terms: D000284:Administration, Oral; D003437:Crotonates / Q000008:administration & dosage*; D017277:Drug Approval / Q000379:methods*; D006801:Humans; D006885:Hydroxybutyrates; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009570:Nitriles; D014052:Toluidines / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D003437:Crotonates; D006885:Hydroxybutyrates; D009570:Nitriles; D014052:Toluidines; C527525:teriflunomide